Critical Comparison: ARS Pharmaceuticals (NASDAQ:SPRY) and Actinium Pharmaceuticals (NYSE:ATNM)
by Jessica Moore · The Cerbat GemARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) and Actinium Pharmaceuticals (NYSE:ATNM – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.
Valuation and Earnings
This table compares ARS Pharmaceuticals and Actinium Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ARS Pharmaceuticals | $30,000.00 | 46,725.08 | -$54.37 million | ($0.52) | -27.81 |
| Actinium Pharmaceuticals | $81,000.00 | 676.55 | -$48.82 million | ($1.71) | -1.08 |
Actinium Pharmaceuticals has higher revenue and earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
ARS Pharmaceuticals has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500.
Profitability
This table compares ARS Pharmaceuticals and Actinium Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ARS Pharmaceuticals | N/A | -19.77% | -19.26% |
| Actinium Pharmaceuticals | N/A | -101.69% | -48.91% |
Institutional & Insider Ownership
68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 40.1% of ARS Pharmaceuticals shares are held by insiders. Comparatively, 4.0% of Actinium Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of current recommendations and price targets for ARS Pharmaceuticals and Actinium Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ARS Pharmaceuticals | 0 | 0 | 4 | 2 | 3.33 |
| Actinium Pharmaceuticals | 0 | 1 | 4 | 0 | 2.80 |
ARS Pharmaceuticals presently has a consensus price target of $24.00, indicating a potential upside of 65.98%. Actinium Pharmaceuticals has a consensus price target of $11.40, indicating a potential upside of 519.57%. Given Actinium Pharmaceuticals’ higher probable upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than ARS Pharmaceuticals.
Summary
ARS Pharmaceuticals beats Actinium Pharmaceuticals on 9 of the 12 factors compared between the two stocks.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company’s research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.